Technology Bundle ID

Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers

Linked ID
Lead Inventors
Scott Hoyt (NCATS)
Chris Finocchio (NCATS)
Craig Thomas (NCATS)
Daniel Starczynowski (Cincinnati Children's Hospital Medical Center)
Gregory Tawa (NCATS)
This technology includes a series of imidazo[1,2-a]pyridines that potently inhibit FLT3, which can be utilized as an anticancer agent. These molecules retain potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML.
Commercial Applications
Used to treat a variety of hematological diseases, including but not limited to AML, myeloid dysplastic syndrome, Diffuse Large B-cell Lymphoma, and other blood cancers.
Competitive Advantages
These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space.

Request More Info

Licensing Contact: